Related references
Note: Only part of the references are listed.346. Factors influencing B cell repopulation after remission induction with rituximab in newly diagnosed, treatment–naïve patients with ANCA-associated vasculitis
Chiara Salviani et al.
RHEUMATOLOGY (2019)
Predicting Severe Infection and Effects of Hypogammaglobulinemia During Therapy With Rituximab in Rheumatic and Musculoskeletal Diseases
Md Yuzaiful Md Yusof et al.
ARTHRITIS & RHEUMATOLOGY (2019)
Rituximab for non-responsive idiopathic membranous nephropathy in a Chinese cohort
Xin Wang et al.
NEPHROLOGY DIALYSIS TRANSPLANTATION (2018)
Efficacy and safety of rituximab for systemic lupus erythematosus-associated immune cytopenias: A multicenter retrospective cohort study of 71 adults
Alexandra Serris et al.
AMERICAN JOURNAL OF HEMATOLOGY (2018)
Trimethoprim-sulfamethoxazole prophylaxis prevents severe/life-threatening infections following rituximab in antineutrophil cytoplasm antibody-associated vasculitis
Andreas Kronbichler et al.
ANNALS OF THE RHEUMATIC DISEASES (2018)
Risk factors for infectious complications of ANCA-associated vasculitis: a cohort study
Liu Yang et al.
BMC NEPHROLOGY (2018)
Long-term efficacy of remission-maintenance regimens for ANCA-associated vasculitides
Benjamin Terrier et al.
ANNALS OF THE RHEUMATIC DISEASES (2018)
A Randomized, Controlled Trial of Rituximab in IgA Nephropathy with Proteinuria and Renal Dysfunction
Richard A. Lafayette et al.
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY (2017)
Rituximab for Severe Membranous Nephropathy: A 6-Month Trial with Extended Follow-Up
Karine Dahan et al.
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY (2017)
Predictors for Mortality in Patients with Antineutrophil Cytoplasmic Autoantibody-associated Vasculitis: A Study of 398 Chinese Patients
Qing-ying Lai et al.
JOURNAL OF RHEUMATOLOGY (2014)
Rituximab versus Azathioprine for Maintenance in ANCA-Associated Vasculitis
L. Guillevin et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Predictors of Treatment Resistance and Relapse in Antineutrophil Cytoplasmic Antibody-Associated Vasculitis A Study of 439 Cases in a Single Chinese Center
Zhi-Ying Li et al.
ARTHRITIS & RHEUMATOLOGY (2014)
2012 Revised International Chapel Hill Consensus Conference Nomenclature of Vasculitides
J. C. Jennette et al.
ARTHRITIS AND RHEUMATISM (2013)
Rituximab for remission induction and maintenance in refractory granulomatosis with polyangiitis (Wegener's) Ten-year experience at a single center
Rodrigo Cartin-Ceba et al.
ARTHRITIS AND RHEUMATISM (2012)
Early mortality in systemic vasculitis: relative contribution of adverse events and active vasculitis
Mark A. Little et al.
ANNALS OF THE RHEUMATIC DISEASES (2010)
Rituximab versus Cyclophosphamide in ANCA-Associated Renal Vasculitis.
Rachel B. Jones et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
Pulse Versus Daily Oral Cyclophosphamide for Induction of Remission in Antineutrophil Cytoplasmic Antibody-Associated Vasculitis A Randomized Trial
Kirsten de Groot et al.
ANNALS OF INTERNAL MEDICINE (2009)
A New Equation to Estimate Glomerular Filtration Rate
Andrew S. Levey et al.
ANNALS OF INTERNAL MEDICINE (2009)
Outcomes from studies of antineutrophil cytoplasm antibody associated vasculitis: a systematic review by the European League Against Rheumatism systemic vasculitis task force
C. Mukhtyar et al.
ANNALS OF THE RHEUMATIC DISEASES (2008)
EULAR recommendations for conducting clinical studies and/or clinical trials in systemic vasculitis: focus on anti-neutrophil cytoplasm antibody-associated vasculitis
Bernhard Hellmich et al.
ANNALS OF THE RHEUMATIC DISEASES (2007)
Pathogenesis of vascular inflammation by anti-neutrophil cytoplasmic antibodies
JC Jennette et al.
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY (2006)
Cinical and pathological characteristics of Chinese patients with antineutrophil cytoplasmic autoantibody associated systemic vasculitides: a study of 426 patients from a single centre
M Chen et al.
POSTGRADUATE MEDICAL JOURNAL (2005)
Share Paper
